Biagio Castaldi^1,*, Francesco Prati¹, Alice Pozza^1,2, Irene Cattapan^1,2, Jennifer Fumanelli^1,2, Domenico Sirico¹, Giovanni Di Salvo¹

Congenital Heart Disease, Vol.19, No.5, pp. 513-533, 2024, DOI:10.32604/chd.2025.058053 - 31 December 2024

Abstract Congenital heart disease (CHD) affects about 1% of live births. Among them, about 20% will undergo one or more surgical or percutaneous maneuvers on the right ventricle outflow tract or pulmonary valve. Transcatheter pulmonary valve implantation is a recently available less invasive alternative to surgery for treatment of right ventricular outflow tract dysfunction. Thus, residual dysfunction can be treated early and with a lower risk profile. This narrative review aimed to describe the state of the art of percutaneous pulmonary valve implantation. More >

Dominique Vervoort^1,2,*, Mimi X. Deng^2,3, Aliya Izumi⁴, Shelby Kutty⁵, Frank Edwin^6,7

Congenital Heart Disease, Vol.19, No.5, pp. 499-511, 2024, DOI:10.32604/chd.2024.057749 - 31 December 2024

Abstract Pediatric and congenital heart disease (PCHD) affects millions of children worldwide, including over one million babies born with congenital heart disease (CHD) each year and 300,000 children dying from rheumatic heart disease (RHD) yearly. Although the vast majority of children born with CHD in high-income countries now reach adulthood and RHD is nearly eradicated in these countries, most of the world cannot access the necessary care to prevent or mitigate PCHD. In low- and middle-income countries, over 90% of children with PCHD cannot receive the care they need, as over 100 countries and territories… More >

Jonathan S. Taylor-Fishwick^1,*, Nicholas Holzemer², Brandon Middlemist³, Vivian Duarte³, Kaitlin E. Olson⁴, Johannes C. von Alvensleben⁵, Megan SooHoo⁶, Amber Khanna⁷

Congenital Heart Disease, Vol.19, No.5, pp. 457-472, 2024, DOI:10.32604/chd.2024.057151 - 31 December 2024

Abstract Background: Post-operative atrial fibrillation (POAF) frequently occurs after cardiac surgery. Although adult congenital heart disease (ACHD) patients have higher rates of arrhythmia than the general population, there is scant literature on POAF in ACHD patients. Objectives: Identify key risk factors associated with post-operative atrial fibrillation and evaluate the short- and mid-term significance of developing POAF. Methods: A retrospective cohort study was conducted of ACHD patients from 2013–2021 at the University of Colorado Hospital and Children’s Hospital of Colorado. The institutional Society of Thoracic Surgeons (STS) surgical registry was used to identify patients ≥18-year-old with congenital heart… More >

William H. Marshall V^1,2,*, Lydia K. Wright²

Congenital Heart Disease, Vol.19, No.4, pp. 419-433, 2024, DOI:10.32604/chd.2024.056608 - 31 October 2024

Abstract Heart failure (HF) is common in patients with congenital heart disease (CHD) and there are limited medical therapies. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a proven medical therapy in patients with acquired HF, though data are limited in patients with CHD. The aim of this review is to summarize the current evidence for use of SGLT2i in patients with CHD and identify future directions for study. In available publications, SGLT2i in patients with CHD seem to be well tolerated, with similar side effect profile to patients with acquired HF. Improvement in functional capacity and natriuretic More >

Sameh M. Said^1,2,*, Yasin Essa¹

Congenital Heart Disease, Vol.19, No.4, pp. 407-417, 2024, DOI:10.32604/chd.2024.055636 - 31 October 2024

Abstract Minimally invasive approaches for cardiac surgery in children have been lagging in comparison to the adult world. A wide range of the most common congenital heart defects in infants and children can be repaired successfully through a variety of non-sternotomy incisions. This has been shown to be associated with superior cosmetic results, shorter hospital stays, and rapid return to full activity compared to sternotomy. These approaches have been around for decades, but they have not been widely adopted for a variety of reasons. Right axillary thoracotomy is one of these approaches that we believe should More >

Catalina Vargas-Acevedo¹, Gareth J. Morgan¹, Rhynn Soderstrom², Richard Ing³, Nicholas Houska³, Jenny E. Zablah^1,*

Congenital Heart Disease, Vol.19, No.4, pp. 389-397, 2024, DOI:10.32604/chd.2024.055121 - 31 October 2024

Abstract Introduction: Pulmonary hemorrhage (PHm) is a life-threatening complication that can occur after catheter-based interventions in patients with pulmonary vein stenosis (PVS). Inhaled racemic epinephrine (iRE) and tranexamic acid (iTXA) have been used in other conditions, but a standardized approach in PVS has not been described. We aimed to describe the current management of PHm after PVS catheter-based interventions. Methods: We present a retrospective review of episodes of PHm from July 2022 to February 2024. PHm was defined as frank blood suctioned from the endotracheal tube including blood-tinged secretions and >3% decrease in saturations and/or ventilatory… More >

Fajri Marindra Siregar^1,2, Sofia Mubarika Haryana³, Dyah Wulan Anggrahini⁴, Lucia Kris Dinarti⁴, Anggoro Budi Hartopo^4,*

Congenital Heart Disease, Vol.19, No.4, pp. 375-388, 2024, DOI:10.32604/chd.2024.054742 - 31 October 2024

Abstract A particular type of endogenous noncoding RNAs known as circular RNAs (circRNAs) has now become possible biomarkers for several diseases because of their stability and tissue-specific expression patterns. CircRNAs might play a role in various of biological processes. The identification of particular circRNAs dysregulated in pulmonary arterial hypertension (PAH) raises the possibility of these molecules serving as biomarkers for the disease’s early diagnosis and treatment. This review mainly summarizes the role and potential of circRNA as a future biomarker in PAH related to congenital heart disease. This study presented several potential circRNA targets as diagnostic More > Graphic Abstract

Wenjie Dong^1,2,#, Zhibin Hong^1,#, Aqian Wang², Kaiyu Jiang², Hai Zhu², Fu zhang², Zhaoxia Guo², Hongling Su^2,*, Yunshan Cao^3,*

Congenital Heart Disease, Vol.19, No.3, pp. 325-339, 2024, DOI:10.32604/chd.2024.052267 - 26 July 2024

Abstract Background: Current guidelines for managing pulmonary arterial hypertension (PAH) recommend a risk stratification approach. However, the applicability and accuracy of these strategies for PAH associated with congenital heart disease (PAH-CHD) require further validation. This study aims to validate the reliability and predictive accuracy of a simplified stratification strategy for PAH-CHD patients over a three-year follow-up. Additionally, new prognostic variables are identified and novel risk stratification methods are developed for assessing and managing PAH-CHD patients. Methods: This retrospective study included 126 PAH-CHD patients. Clinical and biochemical variables across risk groups were assessed using Kruskal-Wallis and Fisher’s… More > Graphic Abstract

Jiawang Xiao, Jianming Wang, Zhongchao Wang, Lili Meng, Ming Zhao, Qiguang Wang^*

Congenital Heart Disease, Vol.19, No.3, pp. 293-303, 2024, DOI:10.32604/chd.2024.051427 - 26 July 2024

Abstract Background: Transcatheter closure (TCC) has emerged as the preferred treatment for selected congenital heart disease (CHD). While TCC offers benefits for patients with postoperative residual shunts, understanding its mid- and long-term efficacy and safety remains crucial. Objective: This study aims to assess the mid- and long-term safety and efficacy of TCC for patients with residual atrial or ventricular septal shunts following CHD correction. Methods: In this consecutive retrospective study, we enrolled 35 patients with residual shunt who underwent TCC or surgical repair of CHD between June 2011 to October 2022. TCC candidacy was determined based on… More >

Shuliang Xia^1,2,3,#, Huikang Tao^2,#, Shixin Su⁴, Xinxin Chen², Li Ma², Jianru Li⁵, Bei Gao⁶, Xumei Liu⁵, Lei Pi⁷, Jinqing Feng⁴, Fengxiang Li², Jia Li^4,*, Zhiwei Zhang^1,3,*

Congenital Heart Disease, Vol.19, No.2, pp. 247-256, 2024, DOI:10.32604/chd.2024.052583 - 16 May 2024

Abstract Aims: Multiple genes and environmental factors are known to be involved in congenital heart disease (CHD), but epigenetic variation has received little attention. Monozygotic (MZ) twins with CHD provide a unique model for exploring this phenomenon. In order to investigate the potential role of Deoxyribonucleic Acid (DNA) methylation in CHD pathogenesis, the present study examined DNA methylation variation in MZ twins discordant for CHD, especially ventricular septal defect (VSD). Methods and Results: Using genome-wide DNA methylation profiles, we identified 4004 differentially methylated regions (DMRs) in 18 MZ twin pairs discordant for CHD, and 2826 genes were… More > Graphic Abstract